Researchers developed an NMR-based method to identify where to chemically modify cyclic peptides, achieving 33% oral bioavailability in rats — a major step toward oral peptide drugs.
33% oral bioavailabilityThe best N-methylated cyclic peptide achieved 33% oral bioavailability in rats — meaning a third of the swallowed dose reached the bloodstream, a strong result for a peptide.
What the researchers found
The researchers used NMR temperature coefficients to rapidly identify exposed amide bonds in cyclic peptides — the spots most vulnerable to water and therefore most in need of protection. By selectively N-methylating these positions, they created peptides with improved membrane permeability.
Five leucine-rich peptide scaffolds were tested with various N-methylation patterns. The most promising derivative (peptide 15) achieved 33% oral bioavailability in a rat model, validated through in vivo testing. The approach was further validated by explaining the known oral bioavailability of a somatostatin analog. Membrane permeability was confirmed using both parallel artificial membrane permeability assay (PAMPA) and Caco-2 cell assays before moving to animal testing.
Why it matters
Most peptide drugs today require injection because they can't survive oral administration. If peptides could be taken as pills, it would transform treatment for conditions like diabetes, growth disorders, and many others. This study provides a faster, more practical method for designing orally available peptides than the traditional approach of solving full 3D structures — potentially accelerating the development of oral peptide therapeutics across the pharmaceutical industry.
How the study worked
The team used NMR spectroscopy to measure temperature coefficients of amide protons in cyclic peptides, which reveals which amide bonds are solvent-exposed versus shielded by intramolecular hydrogen bonds. Exposed amides were selectively N-methylated to reduce water interaction and improve membrane crossing. Membrane permeability was assessed in vitro using PAMPA and Caco-2 cell assays. The top candidate was then tested in vivo in a Wistar rat model to measure actual oral bioavailability.
What this study cannot tell us
The 33% oral bioavailability was demonstrated in rats, which may not directly translate to humans due to differences in gut physiology and metabolism. The peptide scaffolds tested were leucine-rich model peptides without therapeutic targets — applying this approach to bioactive peptides with specific targets could introduce additional constraints. The study focused on membrane permeability as the main barrier to oral availability, but enzymatic degradation and first-pass metabolism are also important factors not fully addressed.
How to read the evidence
This is a well-designed preclinical methodology study published in PNAS, combining NMR structural analysis with in vitro permeability assays and in vivo rat pharmacokinetics. The evidence is strong for the methodological approach but remains preclinical — the peptides tested were model compounds, not therapeutic candidates.
When this study was published
Published in 2014, this study is over a decade old but remains highly relevant. It was ahead of its time — oral peptide delivery has since become one of the hottest areas in pharmaceutical development, with oral semaglutide approved in 2019.
The bigger picture
The oral bioavailability problem is arguably the single biggest barrier limiting peptide therapeutics. While injectable peptides like semaglutide and insulin have been hugely successful, the pharmaceutical industry has invested billions trying to make them orally available. This NMR-guided N-methylation approach, published in PNAS by a team including researchers from Pfizer (Liras and Price), represents a significant methodological advance that has influenced subsequent peptide drug design efforts. The success of oral semaglutide (Rybelsus), approved in 2019, shows that oral peptide delivery is commercially viable — methods like this one help expand the approach to other peptide drugs.
Questions still open
- Can this NMR-guided N-methylation approach be successfully applied to therapeutically active peptides without compromising their biological activity?
- Would the 33% oral bioavailability seen in rats hold up in larger animal models or human pharmacokinetic studies?
- How does this method compare in speed and cost to computational approaches for predicting oral peptide bioavailability?
Common questions
Why can't most peptide drugs be taken as pills?
What is N-methylation and how does it help?
Read the original research
Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients.
Proceedings of the National Academy of Sciences of the United States of America, 111(49), 17504-9
Citation
Wang, Conan K; Northfield, Susan E; Colless, Barbara; Chaousis, Stephanie; Hamernig, Ingrid; Lohman, Rink-Jan; Nielsen, Daniel S; Schroeder, Christina I; Liras, Spiros; Price, David A; Fairlie, David P; Craik, David J. (2014). Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients.. Proceedings of the National Academy of Sciences of the United States of America, 111(49), 17504-9.